Evoke Semaglutide: What the Clinical Evidence Shows

What the STEP 1 trial found, and why it mattered

When the STEP 1 results were published in the New England Journal of Medicine, the scale of weight loss reported was larger than most clinicians had seen from any non-surgical intervention. Over 68 weeks, participants receiving the 2.4mg weekly dose of semaglutide lost around 15% of their starting body weight on average, compared with roughly 2.4% in the placebo group. The trial enrolled adults with obesity or overweight alongside at least one weight-related condition, and all participants followed a reduced-calorie diet and increased their physical activity. Weight loss of that magnitude, sustained over more than a year, placed semaglutide in a different category from earlier medicines.

Those results fed directly into the regulatory process. NICE recommended semaglutide (Wegovy) for NHS use in England under technology appraisal TA875, published in March 2023, for adults with a BMI of 35 or above alongside at least one weight-related comorbidity and as part of a specialist weight management service, for a maximum of two years. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The NHS recommendation is more tightly defined than the medicine's licensed eligibility, which is why many people who qualify for a private prescription do not yet qualify for NHS access.

Since then, the picture has continued to develop. MHRA approval of a 7.2mg dose, covered in detail on our semaglutide 2 page, in early 2026 (with trial data reporting around 20.7% average weight loss over 72 weeks) means semaglutide's ceiling has moved considerably closer to the results seen with tirzepatide in the NICE TA1026 evidence review. That is a meaningful shift for patients who have plateaued at 2.4mg. Dose availability at any given time is confirmed at consultation rather than assumed.

How semaglutide works, and what that means in practice

Semaglutide activates the GLP-1 receptor, a pathway involved in appetite signalling and blood-sugar regulation. The practical effects people notice include a reduced sense of hunger, feeling full more quickly after eating smaller amounts, and less preoccupation with food between meals. Gastric emptying also slows, which contributes to the fullness effect. None of this is willpower; it is pharmacology acting on systems that, for many people with obesity, have been working against weight loss for years.

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and vomiting appear most often in the weeks after starting or after a dose increase, and they typically settle as the body adjusts. Slower titration can help. Serious but less common concerns include acute pancreatitis, the MHRA issued a Drug Safety Update in January 2026 specifically highlighting this risk across GLP-1 medicines. Severe, persistent stomach pain that radiates toward the back warrants prompt medical attention, regardless of whether vomiting is also present.

The NHS semaglutide medicines page sets out the full side-effect profile and the signs that require urgent medical help, and it is worth reading before treatment starts. That takes under a minute to scan, and it is the kind of habit that means you know what to look for rather than searching in the middle of the night.

Who semaglutide is licensed for in the UK, and what private access looks like

The Wegovy licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside a qualifying weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. These are the licensed criteria; a prescriber still assesses the complete clinical picture, including any contraindications, before approving treatment.

For people considering the full range of semaglutide options, it helps to understand that the private route does not require a GP referral or a wait for a specialist appointment. A regulated online pharmacy can issue a private prescription following a clinical assessment. At nume, that assessment is personally reviewed by a GPhC-registered prescriber (not a scoring system) and treatment is dispatched the same day when clinically approved. If you are weighing up options or trying to understand costs before committing, the Wegovy cost page explains what is typically included in a private prescription price.

For those who find injections difficult, the oral semaglutide tablet approved in June 2026 offers an alternative route using the same active ingredient. It is the first oral GLP-1 medicine licensed for weight management in the UK, and it carries its own dosing schedule and taking instructions that differ meaningfully from the injection. A prescriber can help you work out which form suits your situation.

When semaglutide may not be the right fit

Semaglutide is not suitable for everyone. Pregnancy, breastfeeding, and actively trying to conceive are all situations where it is not recommended, and the medicine is not licensed for anyone under 18. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 requires careful consideration. People with a history of pancreatitis or certain gastrointestinal conditions should discuss that history honestly at consultation.

The interaction with oral contraceptives is worth specific attention. NHS guidance notes that women using the pill should add a barrier method for the first four weeks of semaglutide treatment and for four weeks after each dose increase, because absorption of oral medication can be affected as gastric emptying slows. Anyone on HRT or who has surgery planned should also let their clinical team know. These are not reasons to avoid treatment, they are reasons to have a proper clinical conversation.

There are also people for whom tirzepatide, licensed under a dual GIP and GLP-1 mechanism, may produce greater average weight loss based on head-to-head evidence. The semaglutide overview on our site covers that comparison in more detail, and our clinical team is available to help you think through the options. If any aspect of your health history affects how you process mood-regulating medicines, the semaglutide and bipolar disorder page addresses some of the specific questions that come up in that context.

If you have questions or want a prescriber to review your specific situation, you can speak to our prescribers through a free consultation, no referral needed, and no obligation to proceed.